Developing new radiopharmaceuticals for imaging and therapy
As well as providing radiochemistry services to support preclinical PET and SPECT research conducted at Monash Biomedical Imaging, our Radiochemistry team develops novel radiopharmaceuticals for the diagnosis and treatment of various health conditions.
The team, led by Dr Brett Paterson, invites collaborations with industry and academia, and offers postgraduate student opportunities.
Developing metal-based radiopharmaceuticals for imaging and therapy
Personalised medicine will be greatly enhanced with the introduction of new radiopharmaceuticals for the diagnosis and treatment of various cancers, as well as cardiovascular disease and brain disorders.
Dr Brett Paterson and his team are developing the chemistry and radiochemistry to produce new radiometal-based imaging and therapy agents. This work includes the synthesis of new molecules and optimisation of the radiochemistry for preclinical PET, SPECT and biodistribution investigations.